MISSISSAUGA, On, June 4, 2012 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced
healthcare company, today announced that it is presenting its
latest breakthrough antimicrobial products, including the recently
United States FDA cleared IV Clear™, at the 2012 Association for
Professionals in Infection Control and Epidemiology, Educational
Conference and International Meeting ("APIC") from June 4 to 6 in San
Antonio, Texas.
Covalon will be showcasing its latest products such as
ColActive® Plus Ag, which is cleared for use by the FDA in the
management of diabetic ulcers and other chronic wounds, IV Clear
antimicrobial silicone adhesive dressing for vascular access and
SurgiClear™, its unique antimicrobial transparent silicone adhesive
surgical dressing. Covalon will also present several vascular
access, urological and implantable medical devices coated with
Covalon's antimicrobial CovaCoat™ technology.
"APIC 2012 is a great opportunity for Covalon's North American,
European, and Asian customers, medical professionals, and potential
business partners to see our innovative infection prevention and
control products" said Brian Pedlar,
Covalon's Chief Executive Officer.
APIC's Annual Educational Conference and International Meeting
is one of the largest annual gatherings of infection preventionists
in the world. It showcases the latest innovative products,
technologies and services and provides unparalleled opportunities
to engage with infection prevention experts. The 39th Annual
Educational Conference & International Meeting brings together
professionals from across the healthcare continuum, with more than
200 companies and 2,700 attendees expected at this year's
event.
To learn more about Covalon's products and services, please
visit us at booth #235 in the Henry B. Gonzalez Convention Center
in San Antonio, Texas from
June 4 to 6, 2012 or contact Covalon
directly:
Brian Pedlar
CEO, Covalon Technologies Ltd. |
Email:
Phone:
Toll free:
Fax:
Web site:
Twitter: |
bpedlar@covalon.com
905.568.8400 x 233
1.877.711.6055
905.568.5200
www.covalon.com
@covalon |
About Covalon
Covalon Technologies Ltd. researches, develops and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.